A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Registration Number
- NCT06068842
- Lead Sponsor
- AbbVie
- Brief Summary
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC.
Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months.
There is no additional burden for participants in this trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 579
- Previously consented and/or prospective collection of consent for research use of banked biological materials and clinical data.
- Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC).
- Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.
- Specimens collected before 2019.
- Insufficient specimen tissue for testing.
- Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing.
- Adenosquamous and sarcomatous histologies of NSCLC.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence of Mesenchymal Epithelial Transition (MET) protein overexpression (OE) Up to 15 Months OE is defined as: positive: \>= 25% of tumor cells with 3+ staining intensity, or negative: \< 25% of tumor cells with 3+ staining intensity. High overexpression (OE high) is defined as: positive: \>= 50% of tumor cells with 3+ staining intensity negative: \< 50% of tumor cells with 3+ staining intensity. These are determined by an immunohistochemistry (IHC) performed by the local laboratory.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (19)
Burjeel Medical City /ID# 259407
🇦🇪Abu Dhabi, United Arab Emirates
Hospital Alemao Oswaldo Cruz /ID# 256486
🇧🇷Sao Paulo, Brazil
Royal University Hospital /ID# 261272
🇨🇦Saskatoon, Saskatchewan, Canada
Nova Scotia Health Authority /ID# 256950
🇨🇦Halifax, Nova Scotia, Canada
Institut universitaire de cardiologie et de pneumologie de Québec - Université L /ID# 257872
🇨🇦Québec, Quebec, Canada
Rambam Health Care Campus /ID# 256546
🇮🇱Haifa, H_efa, Israel
Kindai University Hospital /ID# 257890
🇯🇵Osakasayama-shi, Osaka, Japan
National Cancer Center Hospital /ID# 257889
🇯🇵Chuo-ku, Tokyo, Japan
The Catholic University of Korea, Yeouido ST. Mary's Hospital /ID# 261511
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
West China Hospital, Sichuan University /ID# 256906
🇨🇳Chengdu, Sichuan, China
UOMi Cancer Center - Clinica Tres Torres /ID# 261212
🇪🇸Barcelona, Spain
Universitätsspital Basel /ID# 256677
🇨🇭Basel Town, Basel-Stadt, Switzerland
Hospital Italiano de Buenos Aires /ID# 256999
🇦🇷Ciudad Autonoma Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina
Instituto Alexander Fleming /ID# 256295
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 256487
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
University Hospital Zurich /ID# 256678
🇨🇭Zurich, Zuerich, Switzerland
National Taiwan University Hospital /ID# 261542
🇨🇳Taipei City, Taipei, Taiwan
Queen's University Belfast /ID# 258458
🇬🇧Belfast, Northern Ireland, United Kingdom
University Hospitals Birmingham NHS Foundation Trust /ID# 260991
🇬🇧Birmingham, United Kingdom